Search
Returning search results with filters:
Remove filter for
Category: Biologic or vaccine
Remove filter for
Issue: COVID
Remove filter for
Last updated: January 2022
Remove filter for
Last updated: 2022
Clear all
Type
Audience
Category
Issue
Last updated
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archived checkbox.
Displaying 1 - 1 of 1 items.
There is a high risk of treatment failure with the casirivimab and imdevimab combination based on analysis of neutralization activity against selected mutations of the SARS-CoV-2 Omicron variant. The Canadian Product Monograph for casirivimab and…
AlertHealth professional risk communication | 2022-01-07